InvestorNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering

Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the closing of its previously announced initial offering. The offering comprised 2,800,000 shares of the company’s common stock at a price of $8.00 per unit to the public, raising a […]